| San Francisco Business Times (blog) That treatment ultimately could displace Genentech Inc.’s Lucentis and Avastin or Regeneron’s Eylea for people with a blinding eye disease called wet age-related macular degeneration, or wet AMD. Data from that 40-patient trial in Australia is expected … Regeneron, Avalanche Collaborate on Eye Disease Gene TherapiesDrug Discovery & Development Regeneron, Avalanche to develop new gene therapy products in ophthalmologyPharmaceutical Business Review |
Source: Wet Macular Degeneration News From Google News
Zennie Abraham | Zennie Abraham or “Zennie62” is the founder of Zennie62Media which consists of zennie62blog.com and a multimedia blog news aggregator and video network, and 78-blog network, with social media and content development services and consulting. Zennie is a pioneer video blogger, YouTube Partner, social media practitioner, game developer, and pundit. Note: news aggregator content does not reflect the personal views of Mr. Abraham.